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ABSTRACT 1 
Background 2 
Irritable bowel syndrome (IBS) and other functional bowel disorders (FBD) are 3 
prevalent disorders with altered microbiota. Prebiotics positively augment gut 4 
microbiota and may offer therapeutic potential. 5 
Objective 6 
To investigate the effect of prebiotics compared to placebo on global response, 7 
gastrointestinal symptoms, quality of life (QoL) and gut microbiota, via systematic 8 
review and meta-analysis of randomized controlled trials (RCTs) in adults with IBS 9 
and other FBD. 10 
Design 11 
Studies were identified using electronic databases, back-searching reference lists 12 
and hand-searching abstracts. RCTs that compared prebiotics to placebo in adults 13 
with IBS or other FBD were included. Two reviewers independently performed 14 
screening, data extraction, and bias assessment. Outcome data were synthesized 15 
using odd ratios (OR), weighted mean differences (WMD) or standardized mean 16 
differences (SMD) using a random-effects model. Sub-analyses were performed for 17 
type of FBD and dose, type and duration of prebiotic. 18 
Results  19 
Searches identified 2332 records, and 11 RCTs were eligible (729 patients). 20 
Response to intervention was 52/97 (54%) for prebiotic and 59/94 (63%) for placebo, 21 
with no difference between groups (OR 0.62; 95%CI 0.07, 5.69; p=0.67).  Similarly, 22 
no differences were found for severity of abdominal pain, bloating and flatulence, and 23 
quality of life score between prebiotics and placebo. However, flatulence severity was 24 
improved by prebiotics at doses ≤6 g/d (SMD -0.35, 95%CI -0.71, 0.00, p=0.05) and 25 
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by non-inulin type fructan prebiotics (SMD -0.34, 95%CI -0.66, -0.01, p=0.04), while 26 
inulin-type fructans worsened flatulence (SMD 0.85, 95%CI 0.23, 1.47, p=0.007). 27 
Prebiotics increased absolute abundance of bifidobacteria (WMD 1.16 log10 copies 28 
16S rRNA gene; 95%CI 0.06, 2.26; p=0.04). No studies were at low risk of bias 29 
across all bias categories. 30 
Conclusions  31 
Prebiotics do not improve gastrointestinal symptoms or quality of life in patients with 32 
IBS or other FBD, but they do increase bifidobacteria. Variations in prebiotic type and 33 
dose impacted symptom improvement or exacerbation. 34 
Keywords: Prebiotics, IBS, FBD, inulin type fructans, galactooligosaccharides  35 
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INTRODUCTION 36 
Functional bowel disorders (FBD) are a ‘spectrum of chronic gastrointestinal disorders 37 
characterized by predominant symptoms or signs of abdominal pain, bloating, 38 
distension, and/or bowel habit abnormalities’ [1]. Irritable bowel syndrome (IBS) is 39 
characterized by abdominal pain associated with changes in defecation. Systematic 40 
reviews report a global prevalence of 11.2% for IBS [2], however recent surveys using 41 
updated definitions report a prevalence of 5.7% for IBS, 9.3% for functional diarrhea, 42 
0.9% for functional bloating [3]. Not only are FBD and IBS prevalent disorders, they 43 
can impact quality of life, are a common cause of consultation with healthcare systems 44 
and treatment satisfaction is variable [4, 5]. 45 
IBS and other FBD share some aspects of etiology, some of which relate to the gut 46 
microbiota. Case-control studies report altered gut microbiota in the majority of people 47 
with IBS [6-8], a key feature of which is lower bifidobacteria [9], a microbial signature 48 
associated with a greater number of days of abdominal pain in both healthy adults and 49 
IBS [10, 11]. Further, gastrointestinal infection leads to a higher likelihood of developing 50 
both IBS or functional diarrhea, implicating the gut microbiota in these FBDs [12]. Low 51 
grade inflammation is present in some people with IBS, which may be mediated via gut 52 
microbiota signaling to the gastrointestinal immune system [13, 14]. Furthermore, 53 
altered pain signaling/visceral hypersensitivity has been reported in both IBS and 54 
functional bloating, which may be influenced by the effect of serotonin on 55 
enterochromaffin cells [1, 15].  56 
Prebiotics are ‘substrates that are selectively utilized by host microorganisms 57 
conferring a health benefit to the host’ [16]. Prebiotics are typically dietary 58 
carbohydrates, with inulin-type fructans (ITF) (fructose polymers) and 59 
galactooligosaccharides (GOS) (galactose polymers) being the most extensively 60 
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studied, however, other novel classes of prebiotic are under investigation [17]. 61 
Extensive studies have demonstrated the capacity of prebiotics to specifically enhance 62 
the growth of bifidobacteria in healthy adults [18]. Additionally, prebiotics have been 63 
shown to increase fecal short chain fatty acids (SCFA) and reduce gut-associated 64 
inflammatory markers [14, 19], thus providing a mechanistic rationale for their role in 65 
managing symptoms in IBS and other FBD.  66 
A systematic review published in 2014 [20] only identified one randomized controlled 67 
trial (RCT) of prebiotics in IBS [21] and its update identified only three RCTs [22] 68 
However, these systematic reviews were specific to IBS rather than more broadly to 69 
FBDs that may share a common etiology, presentation and overlapping symptoms [23] 70 
and the latest did not meta-analyze the three trials [22]. Therefore, the aim of this study 71 
was to investigate the effect of prebiotics compared to placebo on response, 72 
gastrointestinal symptoms, stool form and frequency, quality of life and gut microbiota, 73 
via a systematic review and meta-analysis of RCTs in adults with IBS or other FBD. 74 
METHODS 75 
This review was undertaken in line with recommendations of the Cochrane Handbook 76 
for Systematic Reviews of Interventions [24] and reported in line with the guidelines of 77 
Preferred Reporting Items for Systematic reviews and Meta-Analyses [25]. 78 
Identification, screening, eligibility and inclusion of eligible papers were agreed 79 
between the researchers in advance and published prior to the literature search being 80 
conducted (PROSPERO CRD42017074072).  81 
Eligibility criteria 82 
The inclusion criteria were any RCTs reporting the effect of the administration of a 83 
prebiotic compared to a placebo on patients with IBS or other FBD. Details of the full 84 
inclusion and exclusion criteria are described in Table 1.  85 
7 
 
Studies of patients with functional constipation only were not included because the 86 
presenting symptoms and etiology do not completely overlap with other FBD (e.g. 87 
abdominal pain not a dominant feature as in IBS). In addition, as most prebiotics are 88 
fermentable, non-viscous and non-bulking, there is limited mechanistic rationale for 89 
prebiotics in functional constipation, and because higher bifidobacteria have been 90 
reported in functional constipation compared with other FBD, and therefore inclusion 91 
may have confounded the microbiota findings [26].  92 
Search strategy 93 
Studies were identified through systematic search of electronic databases, hand-94 
searching of conference abstracts, clinical trial databases, and back-searching of 95 
reference lists of all eligible studies.  96 
The following six electronic databases were searched: MEDLINE (US National Library 97 
of Medicine, USA; Ovid interface) from 1946 to November 2018; EMBASE (Elsevier 98 
B.V., The Netherlands; Ovid interface) from 1974 to November 2018; CINAHL 99 
(CINAHL Information Systems, USA, EBSCO host interface) from 1946 to 2018; 100 
CENTRAL (The Cochrane Library, Chichester, Wiley InterScience) for all years; and 101 
Web of Science (ISI Thomson Scientific, UK; Web of Knowledge portal) from 1900 to 102 
November 2018. The final search date was 8 November 2018. Combinations of the 103 
terms ‘prebiotics,’ ‘irritable bowel syndrome’ and ‘functional bowel disorder’ were 104 
searched for as MeSH headings and key or free text words. A list of the search strategy 105 
is presented in Supplemental Table 1.  106 
Hand searching of abstracts from 2007 to 2018 from annual conferences of the 107 
following organizations was undertaken: Digestive Disease Week (Gastroenterology); 108 
British Society of Gastroenterology (Gut), United European Gastroenterology Week 109 
(United European Gastroenterology J); Gastroenterological Society of Australia (J 110 
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Gastroenterol Hepatol); European Society of Neurogastroenterology and Motility 111 
(Neurogastroent Motil); British Dietetic Association (J Human Nutrition Dietetics); 112 
Academy of Nutrition and Dietetics (J Amer Dietetic Assoc / J Academy Nutrition 113 
Dietetics); and the Dietitians Association of Australia (Nutrition & Dietetics).  114 
The clinical trials databases of the World Health Organization (ISCTRN registry) and 115 
the US National Institute of Health (Clinicaltrials.gov) were also searched to identify 116 
completed but unpublished trials. 117 
Screening 118 
References were imported into a bibliographic database and duplicates were removed 119 
automatically (EndNote X7; Thomson Reuters). Titles and abstracts were screened 120 
against the eligibility criteria (Table 1) and two researchers then independently 121 
screened all potentially eligible full text articles against the eligibility criteria (BW, MR). 122 
The percentage agreement in study eligibility and a kappa statistic were calculated to 123 
check concordance between reviewers [24]. Disagreements about study eligibility were 124 
resolved through discussion with a third researcher (KW). 125 
Data extraction 126 
Data were extracted from each eligible study relating to the patient or group, the 127 
intervention, the comparator, outcomes measured and the study design, as detailed in 128 
Table 1. A standardized data extraction sheet was developed, and two reviewers 129 
extracted the data from eligible papers (BW, MR). Discrepancies were reviewed and 130 
resolved. Where papers contained insufficient or missing data, the corresponding 131 
author was contacted for further information.  132 
The Cochrane risk of bias tool was used to assess each study individually. The two 133 
reviewers independently assessed risk of bias using seven domains: adequacy of 134 
randomization, allocation concealment, blinding methods, complete outcome data, 135 
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selective reporting and other sources of bias [24]. Percentage agreement and kappa 136 
statistic were calculated to check concordance between reviewers, and differences 137 
resolved by a third reviewer (KW) [24].  138 
Data synthesis 139 
Meta-analysis was performed where two or more studies reported data for the same 140 
outcome. Data for meta-analyses were entered into proprietary software (RevMan 141 
version 5.3; The Nordic Cochrane Centre, Cochrane Collaboration). For dichotomous 142 
outcomes (e.g. response), frequencies were entered to obtain an odds ratio (OR). For 143 
continuous outcomes that were reported in the same units and measured using the 144 
same tool, a weighted mean difference (WMD) was calculated, whereas for continuous 145 
outcomes that were measured or reported differently, a standardized mean difference 146 
(SMD) was calculated [27], using a random-effects model. For cross-over studies, the 147 
intervention and control periods were entered separately. Where a single study used 148 
several doses of a prebiotic, each dose was treated as a separate study for the meta-149 
analysis, whereby the different prebiotic doses were compared to the control 150 
independently, with the sample size in the control group divided by the number of 151 
different doses to reduce effect-size error as recommended [24]. Forest plots with 95% 152 
CIs were generated for all outcomes.  153 
Heterogeneity between results was assessed using the I2 statistic and the chi-square 154 
test, a P-value <0.10 was used to define significant heterogeneity [24]. I2 statistic 155 
values of 25%, 50% and 75% were defined as low, moderate and high heterogeneity, 156 
respectively [24]. Where heterogeneity was high and outlier studies were observed, 157 
sensitivity analysis was performed and data analysis with and without the outlier study 158 
was reported, as recommended [24]. Publication bias assessment was planned using 159 
funnel plot analysis if the number of available studies was >10. 160 
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Predefined subgroup analyses were planned to investigate differences by: (i) FBD 161 
subtypes (IBS, functional diarrhea etc.); (ii) prebiotic type (ITF, non-ITF); (iii) prebiotic 162 
dose; and (iv) prebiotic duration. 163 
RESULTS 164 
Study identification 165 
A total of 2332 non-duplicated papers were identified by the search strategy. The titles 166 
and abstracts were reviewed and 35 were deemed potentially eligible (Figure 1). The 167 
two reviewers agreed on the eligibility (inclusion/exclusion) of 31/35 (89%) of the 168 
studies, with a kappa statistic of 0.74 representing substantial agreement [28]. Eleven 169 
studies fulfilled the inclusion criteria (Table 2). 170 
Study Characteristics 171 
The 11 eligible RCTs compared a prebiotic intervention to a placebo and involved 729 172 
adult patients with either IBS (8 studies) or other FBD (3 studies). These consisted of 173 
seven studies of ITF, two studies of β-galactooligosaccharides, and one study each of 174 
partially-hydrolyzed guar gum and pectin powder. Ten studies were published in 175 
English and one in Chinese, which was then translated to English [29]. Ten studies 176 
were full articles and one was in abstract form only [30]. Corresponding authors of eight 177 
studies were contacted to obtain supplementary information. Of these, six replied [21, 178 
30-34], and three provided data for inclusion in the analyses [30, 31, 34]. One study 179 
did not report the data on the outcomes of interest despite measuring these [33] and 180 
one study did not report any outcome data in a format that could be meta-analyzed 181 
[35]. Authors were contacted but no further data were supplied.   182 
Clinical outcomes  183 
The results of the meta-analyses are summarized in Table 3.  184 
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Response to treatment 185 
Three studies measured dichotomous overall symptom response to treatment 186 
including 191 patients [32, 36, 37]. Overall, 52/97 (54%) patients responded to the 187 
prebiotic and 59/94 (63%) responded to placebo, with no significant difference between 188 
the groups (OR 0.62; 95% CI 0.07, 5.69; p=0.67; I2=91%, p<0.00001). Subgroup 189 
analysis was possible for FBD type, in which two studies of IBS alone showed no 190 
difference in the odds of response (OR 0.22; 95% CI 0.02, 2.74; p= 0.24; I2=89% 191 
p=0.002) [32, 36], and for dose, in which two studies of prebiotics >6 g/d showed no 192 
difference in odds of response (OR 0.22; 95% CI 0.02, 2.74; p= 0.24; I2=89% p=0.002) 193 
[32, 36], and duration, in which two studies ≥4-weeks showed no difference in odds of 194 
response (OR 1.88; 95% CI 0.27, 13.18; p=0.53; I2=85%, p=0.01) [36, 37], compared 195 
with placebo. 196 
Integrative symptom scores, abdominal pain, bloating and flatulence 197 
A range of integrative symptom scores (subjective global assessment, IBS severity 198 
scoring system (IBS-SSS), visual analogue scales and Likert scales) were measured 199 
in eight studies and sufficient data were reported in seven studies including 538 200 
patients [21, 29, 31, 32, 34, 36, 38]. Prebiotics did not result in a significant difference 201 
in integrative symptom scores compared to placebo (Figure 2). Heterogeneity was 202 
high and an outlier was identified [34] and analysis with (SMD -0.39; 95% CI -1.43, 203 
0.64; p=0.46; I2=97%, p<0.00001) and without (SMD 0.12; 95% CI -0.22, 0.45; p=0.49; 204 
I2=61%, p=0.02) the outlier was performed, which reduced but did not remove 205 
heterogeneity (Supplemental Figure 1). Two studies used the IBS-SSS to measure 206 
symptoms, including 185 patients [31, 38], however prebiotics did not result in a 207 
significantly different IBS-SSS score compared with placebo (WMD -5.4; 95% CI -35.7, 208 
24.9; p=0.73; I2=0%, p=0.59). The study that did not report data for overall symptoms 209 
did present graphs showing no difference in the overall symptoms scores between the 210 
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placebo group and prebiotic group after 4-weeks supplementation with 6 g/d of an ITF 211 
[33].  212 
Severity of individual gastrointestinal symptoms were reported as follows: abdominal 213 
pain in ten studies with sufficient data reported in nine studies (628 patients) [21, 29-214 
32, 34, 36-38], bloating in nine studies with sufficient data reported in eight studies (551 215 
patients) [21, 29, 30, 32, 34, 36-38], and flatulence in seven studies with sufficient data 216 
reported in six studies (374 patients) [21, 32, 34, 36, 38]. Heterogeneity was high, and 217 
an outlier was identified for abdominal pain, bloating and flatulence [34], analysis with 218 
(Figure 2) and without this outlier was performed (Supplemental Figure 1). There were 219 
no significant differences in the severity of any of these symptoms between prebiotic 220 
and placebo, either with or without the outlier. The study that did not report data for 221 
symptom outcomes did present graphs that showed no difference in the severity of 222 
abdominal pain, bloating or flatulence between the placebo group and prebiotic group 223 
after 4-weeks supplementation with 8 g/d of an ITF [35].  224 
Subgroup analyses of the effect on type of FBD, or of prebiotic type, dose and duration 225 
were performed. Due to the outlier contributing disproportionate heterogeneity to 226 
symptom outcomes, symptom analysis is presented here without the outlier and data 227 
including the outlier is presented as Online Supporting Material. There was no effect 228 
on integrative symptom scores, although severity of abdominal pain significantly 229 
improved in the study of FBD but not in the seven studies of IBS.  Improvement in both 230 
abdominal pain and bloating severity with non-ITF prebiotics failed to reach statistical 231 
significance (Figure 3). Severity of flatulence significantly worsened with ITF prebiotics 232 
(Figure 3) (SMD 0.85; 95% CI 0.23, 1.47; p=0.007; I2=57%, p=0.13) and significantly 233 
improved with both non-ITF (Figure 3) (SMD -0.34; 95% CI -0.66, -0.01; p=0.04; I2=0%, 234 
p=0.78) and ≤6 g/d (Figure 4) (SMD -0.35; 95% CI -0.71, -0.00; p=0.050; I2=0%, 235 
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p=0.51) . Data for subgroup analyses without the outlier are presented in Figures 3 and 236 
4 and Supplemental figures 2 and 3. Data for subgroup analyses with the outlier 237 
included are presented in Supplemental figures 4-7. 238 
Stool output 239 
Stool frequency was measured in five studies [21, 30, 34, 36, 38] and stool consistency 240 
was measured in two studies [21, 34]. Data were not meta-analyzed as three of the 241 
five studies included all IBS-subtypes and one study did not categorize by predominant 242 
bowel habit making it not possible to define what a beneficial outcome would be as 243 
patients from either end of the stool output spectrum (IBS-diarrhea, IBS-constipation) 244 
were included. Of these studies, when comparing the effect of prebiotics, neither stool 245 
frequency nor consistency were different between prebiotic and placebo.  246 
One study was conducted only in people with IBS-C however data were not compared 247 
between the placebo and prebiotic for stool frequency [30].   248 
Two studies reported data for incomplete fecal evacuation (90 patients) [30, 37]. 249 
Prebiotics did not reduce severity of incomplete evacuation in patients with IBS or FBD 250 
(SMD 0.03; 95% CI -0.38, 0.45; p=0.88; I2=0%, p=0.33).  251 
Quality of life 252 
Quality of life (QoL) was measured in four studies (322 patients) using either the 253 
validated IBS-QoL questionnaire or the IBS-36 questionnaire [21, 29, 34, 38]. 254 
Prebiotics did not affect QoL scores in IBS or FBD, and no outliers were identified (SMD 255 
0.06; 95% CI -0.14, 0.25; p=0.57 I2=0%, p=0.41). Neither doses of ≤6 g/d (SMD -0.02; 256 
95% CI -0.21, 0.25; p=0.85 I2=0%, p=0.56) or doses of >6 g/d (SMD 0.00; 95% CI -257 
0.77, 0.76; p=0.1, I2=59%, p=0.12) impacted QoL compared with placebo. Subgroup 258 
analysis on type of FBD and type or duration of prebiotic could not be performed due 259 
to insufficient studies in these subgroups.  260 
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Three studies used the validated IBS-QoL questionnaire (239 patients) [21, 29, 38]. 261 
There was no significant effect of prebiotics on IBS-QoL (SMD 0.00; 95% CI -0.31, 262 
0.31; p=0.99 I2=22%, p=0.28). 263 
Anxiety and depression 264 
The Hospital Anxiety and Depression Scale (HADS) was measured in two studies (162 265 
patients) [31, 34]. Prebiotics did not impact HADS scores in IBS or FBD (WMD -0.12; 266 
95% CI -0.83, 0.58; p=0.73; I2=0%, p=0.82). Anxiety was measured in three studies 267 
(171 patients) [21, 31, 37]. Prebiotics did not impact anxiety in IBS or FBD (SMD -0.23; 268 
95% CI -0.54, 0.08; p=0.14; I2=0%, p=0.76). Subgroup analyses were possible for two 269 
studies in IBS specifically showing that prebiotics did not impact anxiety (SMD -0.12; 270 
95% CI -0.59, 0.25; p= 0.52; I2=0%, p=1.00), two studies on prebiotic type showing that 271 
ITF did not impact anxiety (SMD -0.27; 95% CI -0.62, 0.09; p= 0.14; I2=2%, p=0.31), 272 
and on two studies for dose showing that ≤6 g/d did not impact anxiety (SMD -0.24; 273 
95% CI -0.57, 0.08; p= 0.14; I2=0%, p=0.56). There were insufficient studies to meta-274 
analyze the impact of prebiotic duration.  275 
Depression was measured in two studies in IBS only (121 patients) using the HADS 276 
[21, 31]. Prebiotics did not impact depression (SMD -0.23; 95% CI -1.49, 1.02; p=0.71; 277 
I2=0%, p=0.65). 278 
Microbiota outcomes  279 
Fecal microbiota was measured in four studies, [21, 29, 31, 35], with three studies 280 
reporting data for absolute abundance (measured using real-time polymerase chain 281 
reaction)  [29, 31, 35] and one reporting only relative abundance (measured using 282 
fluorescence in situ hybridization) and authors were unable to provide further data [21]. 283 
Therefore, meta-analysis was conducted for absolute abundance only (Figure 5).  284 
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Bifidobacteria 285 
Four studies measured bifidobacteria, three of which reported absolute abundance 286 
(200 patients) [29, 31, 35]. Prebiotics significantly increased bifidobacteria in IBS or 287 
FBDs (WMD 1.16 log10 copies of 16S rRNA gene; 95% CI 0.06, 2.26; p=0.04; I2=92%, 288 
p<0.00001) (Figure 5). The study that did not provide absolute abundance reported 289 
significantly greater relative abundance of bifidobacteria for both 3.5 g/d and 7 g/d of 290 
β-galactooligosaccharide compared to placebo.  291 
Subgroup analyses were possible for two studies of prebiotic type, showing that ITF 292 
increased bifidobacteria abundance (WMD 0.59 log10 copies of 16S rRNA gene; 95% 293 
CI 0.14, 1.03; p= 0.009; I2=22% p=0.26), and two studies of prebiotic dose, showing 294 
that doses >6 g/d increased bifidobacteria abundance (WMD 1.55 log10 copies of 16S 295 
rRNA gene; 95% CI 0.31, 2.78; p= 0.01; I2=88% p=0.004), compared with placebo. It 296 
was not possible for study duration to be meta-analyzed for subgroups as all relevant 297 
studies were 4-weeks or longer. 298 
Lactobacilli 299 
Two studies measured absolute abundance of lactobacilli (164 patients) [29, 31]. 300 
Prebiotics did not impact absolute abundance of lactobacilli in IBS or FBD (WMD 0.22 301 
log10 copies of 16S rRNA gene; 95% CI -0.31, 0.75; p=0.41; I2=66%, p=0.09). Two 302 
different prebiotics were used, ITF prebiotic (5 g/d) increased lactobacilli compared to 303 
the control [31] whereas 24 g/d of pectin did not [29] (Figure 5).  304 
Safety outcomes 305 
There were inadequate data to analyze the number of adverse events and some 306 
patients reported multiple adverse events. Four studies (355 patients) [21, 36-38] 307 
described the number of patients reporting adverse events, with no significant 308 
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difference between the prebiotic and placebo groups (OR 0.77; 95% CI 0.47, 1.26; 309 
p=0.30; I2=0%; p=0.69). 310 
Subgroup analyses were performed where possible and demonstrated no effect in 311 
studies of IBS only (OR 0.85; 95% CI 0.47, 1.55; p=0.59; I2=0%; p=0.60) or for ITF (OR 312 
0.71; 95% CI 0.39, 1.28; p=0.25; I2=0%; p=0.68), non-ITF (OR 0.93; 95% CI 0.38, 2.28; 313 
p=0.87; I2=0%; p=0.41), or for doses ≤6 g/d (OR 0.81; 95% CI 0.42, 1.55; p=0.53; 314 
I2=0%; p=0.52), or doses of >6 g/d (OR 0.71; 95% CI 0.33, 1.54; p=0.39; I2=0%; 315 
p=0.34). Subgroup analyses were not possible for prebiotic duration.  316 
Risk of bias 317 
The risk of bias for individual studies are presented in Figure 6. No studies were at low 318 
risk of bias for all categories and no categories were at low risk of bias across all studies 319 
Data for abdominal pain was presented in 10 studies and therefore a funnel plot was 320 
constructed to detect publication bias (Supplemental figure 8). One study was visually 321 
identified to contribute to asymmetry [34] of the data. The asymmetry may be explained 322 
by true heterogeneity in effect size for this study or by sampling variation given it was 323 
the only study that recruited patients via a database [24]. 324 
DISCUSSION  325 
This systematic review and meta-analysis identified 11 RCTs investigating the effect 326 
of prebiotics in IBS or other FBD on gastrointestinal symptoms, stool output, quality of 327 
life and gut microbiota. Based on the current body of evidence, overall, prebiotics do 328 
not benefit symptom management or improve quality of life in IBS or other FBD, 329 
however they do increase fecal bifidobacteria.  330 
Meta-analysis showed prebiotics did not significantly impact integrative symptom 331 
scores, severity of abdominal pain, bloating or flatulence. However, there was 332 
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considerable heterogeneity in these symptom findings that was explained in part by 333 
the presence of an outlier study and to some degree by variations in prebiotic dose and 334 
type. For example, prebiotics at a dose of ≤6 g/d improved flatulence, but higher doses 335 
did not impact this or any other symptoms. Furthermore, ITF significantly worsened 336 
flatulence, whereas non-ITF (including GOS and guar gum) significantly improved 337 
flatulence. This highlights the importance of considering prebiotic dose and type in both 338 
clinical nutrition practice and research, as well as in the conduct of meta-analyses. 339 
Previous systematic reviews of prebiotics have synthesized data from RCTs in 340 
metabolic syndrome blood biomarkers [39] and chronic kidney disease [40] and 341 
reported significant heterogeneity when meta-analyzing outcomes. Few have 342 
performed subgroup analyses based upon prebiotic type and dose, which may be in 343 
part responsible for the heterogeneity, but also neutralizes any observed benefit or 344 
harm of specific prebiotic doses or types. For these reasons, meta-analyses of prebiotic 345 
interventions should perform subgroup analysis on prebiotic type and dose [41]. 346 
The analysis of the data without the outlier should be interpreted with caution and 347 
should be considered alongside the analyses of all studies together as presented in 348 
Figure 2 and Supplemental figures 4-7. The outlier study [34] reported significant 349 
benefit over placebo for all symptoms however the effect sizes were much greater than 350 
for similar studies including one that used a similar dose of the same prebiotic [21]. 351 
Therefore, symptom analysis was too heterogeneous to be able to detect meaningful 352 
differences when all data were combined. The reason for the results seen in this outlier 353 
is unclear except that the participants were selected from a database and this may 354 
have introduced recruitment bias.  355 
Subgroup analysis of duration of prebiotics did not provide insight into the length of 356 
time a prebiotic should be trialed, although this is likely owing to the limited data 357 
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available. A recent proof of concept study in healthy adults supplemented with 2.8 g/d 358 
of GOS for three weeks reported an adaptation period where initial consumption led to 359 
increased flatulence, which had subsided by three weeks, indicating that patients 360 
should take a prebiotic for a minimum of three weeks to ascertain if it will be of benefit 361 
to them [42].  362 
The gut-brain axis is a mechanism hypothesized to be involved in the etiology of IBS 363 
and other FBD. Patients with IBS score lower on QOL scales than healthy controls and 364 
IBS is associated with anxiety related co-morbidities [4, 5]. The meta-analysis did not 365 
support a role for prebiotics in improving QOL, anxiety or depression in patients with 366 
IBS or other FBD, neither did subgroup analysis find any effect for dose, type or 367 
duration of prebiotics. However, only four studies included quality of life and/or 368 
psychological outcome measures and each of the four used a different type of prebiotic 369 
making the results too heterogenous to draw firm conclusions.  370 
The majority of the RCTs that have investigated the effect of prebiotics on IBS and 371 
other FBD used ITF, with subgroup analysis showing a worsening of flatulence. This is 372 
in line with current understanding of one of the mechanisms underpinning a diet 373 
commonly used for treating IBS that is low in ITF and other fermentable oligo-, di-, 374 
mono- saccharides and polyols (low FODMAP diet). The low FODMAP diet aims to 375 
reduce small bowel water content and colonic gas production through specific 376 
carbohydrate restriction [43]. Clinical trials have shown that the low FODMAP diet is 377 
effective in managing symptoms in 50-80% of patients with IBS, although the effect on 378 
the gastrointestinal microbiota may be of concern as it has been shown to specifically 379 
reduce fecal bifidobacteria [44, 45]. Further, the low FODMAP diet has been 380 
demonstrated to alleviate common symptoms of FBDs and IBS such as loose stool, 381 
urgency, abdominal bloating, abdominal pain and flatulence [44-47].  382 
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Due to the effectiveness of restricting fermentable carbohydrates on the low FODMAP 383 
diet, it seems contradictory that supplementation with prebiotic fermentable 384 
carbohydrates would also decrease symptoms in IBS and may relate to differences in 385 
chemical structure and microbial metabolism. The GOS in foods such as beans, pulses 386 
and legumes are α-GOS (i.e. raffinose, stachyose and verbascose) and produce gas 387 
on fermentation and are therefore restricted on the low FODMAP diet along with ITF 388 
[48]. However, non-ITF prebiotic supplements that were shown to significantly reduce 389 
flatulence (with the effect on abdominal pain and bloating approaching significance) in 390 
the current meta-analysis included β-GOS, which in contrast to α-GOS,  are specifically 391 
metabolized by bifidobacteria that produce less gas [17, 49]. Further, frequency of mild 392 
distension, borborygmi and flatulence increased with ITF dose in healthy adults, and 393 
short-chain ITF are fermented more rapidly than longer chain ITF indicating that both 394 
the dose and structure of prebiotics are important [50]. ITF stimulate similar volumes 395 
of colonic gas in both healthy individuals and patients with IBS, however the induction 396 
of abdominal pain and discomfort only occurs in the latter [51]. This suggests that IBS 397 
is more complex than merely the volume of colonic gas production and is likely related 398 
to colonic hypersensitivity.  399 
Although not included in this review, the use of prebiotics in functional constipation has 400 
been investigated in two systematic reviews [20, 52], identifying three trials [53-55]. In 401 
elderly subjects, prebiotics increased bifidobacteria and led to increased passage of 402 
stool and softer stool form compared to placebo [53, 54], however in women with 403 
constipation a mixture of ITF and PHGG (doses undefined) showed no benefit over 404 
placebo for any symptoms [55].  405 
Gastrointestinal microbiota is implicated in IBS, with acute gastroenteritis and water-406 
borne infections increasing the odds of developing IBS up to eight years later [56, 57]. 407 
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In the current study it was found that prebiotic supplementation significantly increased 408 
fecal bifidobacteria abundance compared to placebo in patients with IBS and other 409 
FBD. A recent meta-analysis confirmed that established prebiotic fibers (ITF, GOS) 410 
and novel prebiotic fibers (e.g. arabinoxylan-oligosaccharide, manno-oligosaccharide, 411 
resistant starch, xylo-oligosaccharide) increase bifidobacteria in healthy people, 412 
whereas non-prebiotic fibers did not [18]. This meta-analysis confirms these findings in 413 
people with IBS with both β-GOS and pectin powder, demonstrating an increase in 414 
relative and absolute abundance of bifidobacteria respectively [21, 29]. One 415 
mechanism of action of prebiotics in IBS may therefore be the modulation of the altered 416 
microbiota. Although proving the prebiotic effect is a mechanism, and not merely an 417 
epiphenomenon, in any potential clinical effect in IBS is challenging given the lack of 418 
validated animal models of IBS that would enable microbiome manipulation.  419 
This is the largest systematic review and only meta-analysis to investigate the effect of 420 
prebiotic supplementation in IBS and other FBD on response, gastrointestinal 421 
symptoms, quality of life and gut microbiota. Broad inclusion criteria were used to 422 
identify all placebo-controlled trials to shed light on this under-researched, yet clinically-423 
relevant question. As a consequence, the broad inclusion criteria enabled the inclusion 424 
of one study that was designed to investigate if high-dose ITF prebiotics (19 g/d) could 425 
induce symptoms compared to a placebo in patients that had previously responded to 426 
a low FODMAP diet [32]. It is likely that this introduced significant bias in favor of the 427 
placebo. Nonetheless, when this study was excluded from the meta-analysis the 428 
overall findings for response (OR 1.88, 95% CI 0.27, 13.18, P=0.53) and integrative 429 
symptom score (SMD -0.02, 95% CI -0.22, 0.17, P=0.83) remained non-significant.  430 
This meta-analysis used a robust design in line with PRISMA guidelines and the 431 
protocol was defined and published prior to the literature searches taking place, thus 432 
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limiting the potential for reviewer bias. However, the findings are limited by the small 433 
number of RCTs conducted. A further limitation is the varied methodology used by 434 
authors in defining IBS and other FBD. The data were largely heterogeneous but 435 
overall suggested that the net effect of prebiotics on clinical outcomes is neutral. Non-436 
ITF prebiotics show some promise in individual symptom improvement however these 437 
results came from pooling data from different types of prebiotics and so the strength of 438 
this conclusion is weak.  439 
Conclusion 440 
In conclusion the current review suggests that overall prebiotics do not affect response, 441 
gastrointestinal symptoms or quality of life in patients with FBD or IBS, but they do 442 
increase bifidobacteria. Further, subgroup analysis revealed that neither type, dose nor 443 
duration influenced overall symptoms. Differences were seen between type and dose 444 
on individual symptoms, including that non-ITF prebiotics improved flatulence whereas 445 
ITF worsened flatulence, whilst prebiotics at a dose of ≤6 g/d reduced flatulence 446 
whereas higher doses had no effect. This review did not find sufficient evidence to 447 
establish an optimal duration of treatment.  448 
Overall the quality of evidence is poor across studies investigating the effect of 449 
prebiotics on symptoms, QoL and microbiota in IBS and FBD, and this review highlights 450 
the need for more clinical trials of robust design and may direct future researchers 451 
towards lower dose, novel prebiotics rather than conducting further trials of ITF type 452 
prebiotics in patients with IBS or FBD. Further studies investigating the role of non-ITF 453 
and of novel prebiotics in symptom management and modulation of gut microbiota in 454 
IBS and other FBD should be performed in order to clarify the compounds most likely 455 
to impact symptoms.  456 
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Table 1: Table of inclusion and exclusion criteria following the PICOS1 approach 
PICOS1  Inclusion and exclusion criteria 
 
Data extraction 
Participants 
 
Adult populations ≥18 and ≤64 with IBS (any subtype) or FBD as defined by the authors 
were included. Studies with a median age between these values were eligible. 
Participants with drug-induced constipation or diarrhea, inflammatory bowel disease, 
acute gastrointestinal disorders (e.g. traveler’s diarrhea) or functional constipation alone 
were excluded, unless data specifically for participants with IBS or other FBD alone could 
be extracted. 
 
Age, sex, IBS subtype, type of FBD, method 
for diagnosis, setting, location, number of 
patients of each IBS-subtype randomized to 
intervention and comparator groups, inclusion 
and exclusion criteria. 
Intervention 
 
Prebiotics defined as ITF, GOS, or any other compound defined by the author as a 
prebiotic if justification for the compound fulfilling criteria as a prebiotic were explicitly 
stated. Prebiotics to be administered at a dose of >1 g/d for a minimum of one week and 
could be presented as powders, capsules, tablets, softgel, or fortified food forms. Trials 
that included other interventions (e.g. drug use) were included if the effect of the prebiotic 
alone could be isolated. Multiple intervention arms were eligible.  
Trials of symbiotic were excluded, unless there was an arm of prebiotic alone. 
 
Prebiotic type, dose, frequency, formulation, 
extraction method, degree of polymerization, 
degree of purity and duration of intervention, 
compliance. 
Comparators 
 
Only trials that used a placebo control were eligible. The effect of the prebiotic alone had 
to be able to be isolated.  
Trials where the comparator did not allow the effect of the prebiotic alone to be isolated 
were excluded (e.g. prebiotic versus probiotic). 
 
Type and dose of comparator, compliance. 
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Outcomes 
 
Trials reporting clinical subjective and objective outcome data including IBS or other FBD 
response, symptoms, quality of life, stool form and frequency and gut microbiota were 
included.  
 
Outcomes measured, method of assessment. 
Acceptability and compliance measures, and 
adverse events. 
Study design 
 
Only randomized controlled trials with ≥2 study groups, where it was possible to extract 
data on just the prebiotic vs placebo interventions were included. Both parallel and 
crossover trial design were eligible. 
 
Type of study design, intention to treat 
analysis, number of excluded patients, 
adequacy of randomization and blinding 
methods of participants and investigators.  
1PICOS: Participants, Intervention, Comparator, Outcome, Study type; IBS: Irritable Bowel Syndrome; FBD: Functional Bowel Disorder. 
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Table 2: Characteristics of eligible studies 
Study Country  
Trial 
Design Blinding 
Outcomes 
Included 
in Meta-
analysis  
Sample 
size (% 
female) 
FBD or IBS 
(subtypes) Prebiotic Form Dose Duration 
Azpiroz 2017a [35] Spain Parallel Double  
Symptoms, 
microbiota 
40 (NR) FBD unclassified Inulin Powder  8 g/d 4 weeks 
Azpiroz 2017b [31]  
France 
and Spain 
Parallel Double 
Symptoms, 
microbiota 
79 (39) IBS (all subtypes) 
Short-chain fructo-
oligosaccharide 
Powder  5 g/d 4 weeks 
Hunter 2009 [33] UK Cross-over Double Symptoms 21 (81) IBS (all subtypes) Oligofructose Powder  6 g/d 4 weeks 
Isakov 2013 [30] Russia Parallel Unclear Symptoms 40 (NR) IBS-C    Inulin Yogurt 3 g/d 2 weeks 
Niv 2016 [38] Israel Parallel Double 
Symptoms, 
QoL 
108 (66) IBS (all subtypes) 
Partially hydrolyzed 
guar gum 
Powder 
sachet 
6 g/d  
(3 g/d for first week) 
12 weeks 
Olesen and 
Gudmand-Hoyer 
2000 [36] 
Denmark Parallel Double Symptoms 98 (82) IBS (all subtypes) 
Fructo-
oligosaccharide  
Powder 
20 g/d  
(10 g/d for first two 
weeks) 
12 weeks 
Paineau 2008 [37] France Parallel Double 
Symptoms, 
QoL 
105 
(NR) 
FBD mixed 
Short-chain fructo-
oligosaccharide 
Powder 5 g/d 6 weeks 
Shepherd 2008 [32] Australia Cross-over Double Symptoms 24 (92) 
IBS (all subtypes) LFD 
responsive + fructose 
malabsorption 
Oligofructose  
Orange 
flavored 
drink 
19 g/d  
(7 g for 3-days,   
14 g for 3-days 19 g 
for 8-days)  
2 weeks 
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Silk 2009 [21] UK Parallel Double 
Symptoms, 
QoL, 
microbiota 
44 (64) IBS (all subtypes) 
β-
galactooligosacchar
ide  
Flavored 
powder 
3.5 g/d or 7 g/d 4 weeks 
Vulevic 2018 [34] UK Cross-over Double 
Symptoms, 
QoL 
83 (57) 
FBD (moderate to 
severe) 
β-
galactooligosacchar
ide 
Powder 2.75 g/d 2 weeks 
Xu 2015 [29] China  Parallel Double 
Symptoms, 
QoL, 
microbiota 
87 (55) IBS-D Pectin powder Powder  24 g/d 6 weeks 
All trials except Vulevic (2018) [34] were conducted in primary care setting and all included a placebo control group or treatment period if cross-over design was used.  
NR: not reported; LFD: low FODMAP diet; QoL: Quality of life, IBS: irritable bowel syndrome, FBD: functional bowel disorder 
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Table 3: Results of the meta-analysis comparing prebiotics to placebo for symptoms, quality of life, microbiota and adverse events in 
patients with IBS or FBD
       Results Heterogeneity 
Outcome 
No of studies in meta-
analysis (reference nos.) 
Patients 
(n) 
Meta-analysis overall estimate 
(95% CI) P 
Chi-square 
test P I2 (%) 
Response to treatment 3 [32, 36, 37] 191 OR 0.62 (0.07, 5.69) 0.67 21.47  <0.00001 91 
IBS-SSS 2 [31, 38] 185 WMD -5.40 (-35.70, 24.90) 0.73 0.3 0.59 0 
Incomplete evacuation 2 [30, 37] 90 SMD 0.03 (-0.38, 0.45) 0.88 0.94 0.33 0 
Quality of life 4 [21, 29, 34, 38] 322 SMD 0.06 (-0.14, 0.25) 0.57 1.4 0.41 0 
Anxiety 3 [21, 31, 37] 171 SMD -0.23 (-0.54, 0.08) 0.14 1.19 0.76 0 
Depression 2 [21, 31] 121 WMD -0.23 (-1.49, 1.02)  0.71 0.86 0.65 0 
Bifidobacteria 3 [29, 31, 35] 200 WMD 1.16 (0.06, 2.26) 0.04 24.3 <0.00001 92 
Lactobacilli 2 [29, 31] 164 WMD 0.22 (-0.31, 0.75) 0.41 2.94 0.09 66 
Adverse events 4 [21, 36-38] 355 OR 0.77 (0.47, 1.26) 0.30 2.25 0.69 0 
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FIGURE LEGENDS 
 
Figure 1: PRISMA flow diagram of studies in systematic review. 
Figure 2: Forest plot of integrative symptom score, severity of abdominal pain, 
bloating, and flatulence in randomized controlled trials comparing prebiotic to placebo 
in adults with IBS or other FBD. Values were calculated as standardized mean 
differences (95% CI) for clinical outcomes using a random effects model. 
Figure 3: Forest plot of subgroup analysis of prebiotic type (inulin type fructan versus 
non-inulin type fructan) on integrative symptom score, severity of abdominal pain, 
bloating, and flatulence in randomized controlled trials comparing prebiotic to placebo 
in adults with IBS or other FBD. One outlier study was removed, and values were 
calculated as standardized mean differences (95% CI) for clinical outcomes using a 
random effects model. 
Figure 4: Forest plot of subgroup analysis of different prebiotic dose (≤6 g/d vs >6 g/d) 
on integrative symptom score, severity of abdominal pain, bloating, and flatulence in 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other 
FBD. One outlier study was removed, and values were calculated as standardized 
mean differences (95% CI) for clinical outcomes using a random effects model. 
Figure 5: Forest plot of absolute abundance of fecal bifidobacteria and lactobacilli in 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other 
FBD. Values were calculated as weighted mean differences (95% CI) using a random 
effects model. 
Figure 6: Risk of bias in A: individual studies and B: overall for each category of 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other 
FBD. 
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Azpiroz 2017b [31] 0.1562 0.2284 1 2.8% 0.1 6 [-0.29, 0.60] 
Niv 2016 [38] -0.11 59 0.1 934 12.9% -0.12 [-0.49, 0.26] 
Olesen 2000 [36] 0.2022 0.2048 1 2.8% 0.20 [-0.20, 0.60] 
Shepherd 2008 [32] 1.1 533 0.3294 12.5% 1.1 5 [0.51,1.80] 
Silk 2009 high dose [21] 0.1257 0.4633 11.9% 0.13 [-0.78,1.03] 
Silk 2009 low dose [21] -0.5502 0.4604 11.9% -0.55 [-1.45, 0.35] 
Vulevic 2018 [34] -3.8025 0.2601 12.7% -3.80 [-4.31, -3.29] 
Xu 201 5 [29] 
Subtotal (95% Cl) 
-0.265 13.296 12.6% 
100.0% 
-0.27 [-0.85, 0.32] 
-0.39[-1.43, 064 
] 
1.1.1 Integrative symptom score 
Testfor overall effect Z = 0 74 (P- 0 46) 
1.1.2 Abdominal pain 
    
Azpiroz 2017b [31] 0.31 99 0.2296 1 0.2% 0.32 [-0.1 3, 0.77] 
Isakov 2013 [30] -0.7276 0.3265 1 0.0% -0.73 [-1.37, -0.09] 
Niv 2016 [38] -0.053 0.1 933 1 0.3% -0.05 [-0.43, 0.33] 
Olesen 2000 [36] 0.2075 0.2487 1 0.2% 0.21 [-0.28, 0.69] 
Paine.au 2008 [37] -0.7363 0.2925 1 0.1 % -0.74 [-1.31, -0.1 6] 
Shepherd 2008 [32] 1.031 3 0.3247 1 0.0% 1.03 [0.39,1.67] 
Silk: 2009 high dose [21] -0.3924 0.4669 9.6% -0.39 [-1.31,0.52] 
Silk 2009 low dose [21] -0.8525 0.4703 9.6% -0.85 [-1.77, 0.07] 
Vulevic 2018 [34] -7.0145 0.4151 9.8% -7.01 [-7.83,-6.20] 
Xu 201 5 [29] -0.295 0.2159 1 0.2% -0.29 [-0.72, 0.1 3] 
Subtotal (95% Cl)   100.0% -0.83 [-1.84, 0.18] 
Heterogeneity: Tau’ = 2.13; Chi’= 211.70, df= 7 (P < 0.00001); la = 97% 
Test for overall effect Z = 1 61 (P = 0 11) 
1.1.3 Bloating 
    
Isakov 2013 [30] 0.1975 0.317 11.1 % 0.20 [-0.42, 0.82] 
Niv 2016 [38] -0.2301 0.1 939 11.4% -0.23 [-0.61,0.1 5] 
Olesen 2000 [36] 0.2484 0.2492 11.3% 0.25 [-0.24, 0.74] 
Paine.au 2008 [37] -0.1271 0.2833 11.2% -0.13 [-0.68, 0.43] 
Shepherd 2008 [32] 1.1 533 0.3294 11.1 % 1.1 5 [0.51,1.80] 
Silk 2009 high dose [21] 0.448 0.468 1 0.7% 0.45 [-0.47,1.37] 
Silk 2009 low dose [21] -0.611 6 0.462 1 0.7% -0.61 [-1.52,0.29] 
Vulevic 2018 [34] -5.7464 0.351 5 11.1 % -5.75 [-6.44,-5.06] 
Xu 2015 [29] -0.5257 0.2184 11.4% -0.53 [-0.95, -0.1 0] 
Subtotal (95% Cl)   100.0% -0.57 [-1.67, 0.52] 
Heterogeneity: Taua = 2.56; Chi’= 295.85, df= 9 (P < 0.00001); la= 97% 
Heterogeneity: Tau2= 2.72; Chi3 = 269.26, df= 8 (P < 0.00001); P= 97% 
 
Test for overall effect: Z = 0.69 (P = 
0.49)  ------ 1 ------ 1 -----  ------1 ------ 1 ---- 
-4 -2 2 4 
Favors prebiotic Favors placebo 
Figure 2 
Test for overall effect: Z = 1.03 (P = 0.30) 
1.1.4 Flatulence 
    
Niv 2016 [38] -0.3042 0.1944 17.0% -0.30 [-0.69, 0.08] 
Olesen 2000 [36] 0.5662 0.2587 16.9% 0.57 [0.06,1.07] 
Shepherd 2008 [32] 1.2053 0.331 6 16.7% 1.21 [0.56,1.86] 
Silk: 2009 high dose [21] -0.21 84 0.4641 16.2% -0.22 [-1.1 3, 0.69] 
Silk 2009 low dose [21] -0.6347 0.4627 16.2% -0.63 [-1.54, 0.27] 
Vulevic 2018 [34] -3.771 2 0.2587 1 6.9% -3.77 [-4.28,-3.26] 
Subtotal (95% Cl)   100.0% -0.53 [-2.04, 
0.98] 
Heterogeneity: Tau’= 3.43; Chi3 203.00, df= 5 (P < 0.00001); l== 98% 
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Supplemental figure 1 Forest plot of integrative symptom score, severity of abdominal pain, 
bloating, and flatulence in randomized controlled trials comparing prebiotic to placebo in adults 
with irritable bowel syndrome (IBS) or other functional bowel disorder (FBD) with outlier study 
separated. Values were calculated as standardized mean differences (95% CI) for clinical outcomes 
using a random effects model. 
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Supplemental figure 2 Forest plot of subgroup analysis of bowel disorder type IBS vs other FBD on 
integrative symptom score, severity of abdominal pain, bloating, and flatulence in randomized 
controlled trials comparing prebiotic to placebo in adults with IBS or other FBD. One outlier study 
was removed, and values were calculated as standardized mean differences (95% CI) for clinical 
outcomes using a random effects model. 
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Supplemental figure 3 Forest plot of subgroup analysis of prebiotic duration (<4 weeks vs ≥4 
weeks) on integrative symptom score, severity of abdominal pain, bloating, and flatulence in 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other FBD. One 
outlier study was removed, and values were calculated as standardized mean differences (95% CI) 
for clinical outcomes using a random effects model. 
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Supplemental figure 4 Forest plot of subgroup analysis of prebiotic type (inulin type fructan versus 
non-inulin type fructan) on integrative symptom score, severity of abdominal pain, bloating, and 
flatulence in randomized controlled trials comparing prebiotic to placebo in adults with IBS or 
other FBD. Values were calculated as standardized mean differences (95% CI) for clinical outcomes 
using a random effects model. The outlier study is included in the forest plot. 
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Supplemental figure 5 Forest plot of subgroup analysis of different prebiotic dose (≤6 g/d vs >6 
g/d) on integrative symptom score, severity of abdominal pain, bloating, and flatulence in 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other FBD. One 
outlier study was removed, and values were calculated as standardized mean differences (95% CI) 
for clinical outcomes using a random effects model. The outlier study is included in the forest plot. 
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Supplemental figure 6 Forest plot of subgroup analysis of bowel disorder type IBS vs other FBD on 
integrative symptom score, severity of abdominal pain, bloating, and flatulence in randomized 
controlled trials comparing prebiotic to placebo in adults with IBS or other FBD. Values were 
calculated as standardized mean differences (95% CI) for clinical outcomes using a random effects 
model. The outlier study is included in the forest plot. 
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Supplemental figure 7 Forest plot of subgroup analysis of prebiotic duration (<4 weeks vs ≥4 
weeks) on integrative symptom score, severity of abdominal pain, bloating, and flatulence in 
randomized controlled trials comparing prebiotic to placebo in adults with IBS or other FBD. Values 
were calculated as standardized mean differences (95% CI) for clinical outcomes using a random 
effects model. The outlier study is included in the forest plot. 
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Supplemental figure 8 Funnel plot of abdominal pain outcome in randomized controlled trials 
comparing prebiotic to placebo in adults with IBS or other FBD. 
 
 
 
 
 
